CymaBay Therapeutics Inc. (CBAY)
CymaBay Therapeutics Statistics
Share Statistics
CymaBay Therapeutics has 114.78M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 114.78M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 96.64M |
| Failed to Deliver (FTD) Shares | 171 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -23.81 and the forward PE ratio is null. CymaBay Therapeutics's PEG ratio is 0.89.
| PE Ratio | -23.81 |
| Forward PE | n/a |
| PS Ratio | 80.73 |
| Forward PS | null |
| PB Ratio | 8.58 |
| P/FCF Ratio | -34.37 |
| PEG Ratio | 0.89 |
Enterprise Valuation
CymaBay Therapeutics has an Enterprise Value (EV) of 2.42B.
| EV / Sales | 77.77 |
| EV / EBITDA | -28.18 |
| EV / EBIT | -33.32 |
| EV / FCF | -33.11 |
Financial Position
The company has a current ratio of 10.96, with a Debt / Equity ratio of 0.39.
| Current Ratio | 10.96 |
| Quick Ratio | 10.96 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | -1.34 |
| Debt / FCF | -1.57 |
| Interest Coverage | -5.37 |
Financial Efficiency
Return on Equity is -36.05% and Return on Invested Capital is -25%.
| Return on Equity | -36.05% |
| Return on Assets | -24.24% |
| Return on Invested Capital | -25% |
| Revenue Per Employee | $307.65K |
| Profits Per Employee | $-1.04M |
| Employee Count | 101 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0.32, so CymaBay Therapeutics's price volatility has been higher than the market average.
| Beta | 0.32 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 28.94 |
| 200-Day Moving Average | 18.65 |
| Relative Strength Index (RSI) | 80.99 |
| Average Volume (20 Days) | 3.94M |
Income Statement
In the last 12 months, CymaBay Therapeutics had revenue of 31.07M and earned -105.37M in profits. Earnings per share was -0.99.
| Revenue | 31.07M |
| Gross Profit | 30.39M |
| Operating Income | -101.68M |
| Net Income | -105.37M |
| EBITDA | -85.74M |
| EBIT | -86.42M |
| Earnings Per Share (EPS) | -0.99 |
Balance Sheet
The company has 206.53M in cash and 114.49M in debt, giving a net cash position of 92.04M.
| Cash & Cash Equivalents | 206.53M |
| Total Debt | 114.49M |
| Net Cash | 92.04M |
| Retained Earnings | -978.23M |
| Total Assets | 434.69M |
| Working Capital | 366.96M |
Cash Flow
In the last 12 months, operating cash flow was -72.53M and capital expenditures -445K, giving a free cash flow of -72.98M.
| Operating Cash Flow | -72.53M |
| Capital Expenditures | -445K |
| Free Cash Flow | -72.98M |
| FCF Per Share | -0.69 |
Margins
Gross margin is 97.81%, with operating and profit margins of -327.23% and -339.1%.
| Gross Margin | 97.81% |
| Operating Margin | -327.23% |
| Pretax Margin | -339.1% |
| Profit Margin | -339.1% |
| EBITDA Margin | -275.94% |
| EBIT Margin | -327.23% |
| FCF Margin | -234.85% |
Dividends & Yields
CBAY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.2% |
| FCF Yield | -2.91% |
Analyst Forecast
Currently there are no analyst rating for CBAY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 12.9 |
| Piotroski F-Score | 4 |